Merck goes all-in on a late-stage NASH drug from NGM as development race heats up
After betting $450 million in cash on NGM’s R&D capabilities, Merck R&D chief Roger Perlmutter is adding another $20 million ante to pick up rights …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
